29 unknown, 17 completed, 12 recruiting, 6 active not recruiting. 48 Phase 1, 31 Phase 2, 5 Early Phase 1, 3 Not applicable, 3 Phase 3.
Follow B Cell Lymphoma: new trials by email Literature Review of B Cell Lymphoma trials Research Report on B Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma. CD19/22 CAR-T cells - Acute Lymphobkastic Leukemia, B Cell Lymphoma | Phase 1 / Phase 2 | Enrolling by invitation | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 17 | 2026-10-10 | 2026-10-16 |
| Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma Biological sample collection and immunomonitoring - B Cell Lymphoma, Multiple Mieloma | Not applicable | Not yet recruiting | Centre Henri Becquerel | 45 | 2026-09-18 | 2026-10-01 |
| Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma Immunoglobulin, antibiotic prophylaxis - Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 228 | 2026-09-01 | 2026-08-10 |
| Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) Experimental Intervention - B Cell Malignancies, B-cell Leukemia | Phase 1 | Not yet recruiting | University Hospital, Basel, Switzerland | 12 | 2026-06-01 | 2025-12-24 |
| CD30 CAR-T in the Treatment of CD30 Positive Lymphoma chimeric antigen receptor gene modified T cells - Lymphoma, B Cell Lymphoma | Early Phase 1 | Suspended | Shandong Qilu Cell Therapy Engineering Technology Co., Ltd | 15 | 2026-03-01 | 2026-09-28 |
| Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma Rituximab, Zanubrutinib - Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma | Phase 4 | Recruiting | The First Affiliated Hospital of Soochow University | 40 | 2025-11-01 | 2025-12-08 |
| Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell Lymphoma Maintenance Therapy Group - B Cell Lymphoma | Not yet recruiting | Beijing GoBroad Hospital | 40 | 2025-09-20 | 2025-09-30 | |
| BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma CAR19TIF cells, Fludarabine, Cyclophosphamide - B Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2025-06-20 | 2025-06-25 |
| A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors RN1101 injection - B Cell Lymphoma, Multiple Myeloma | Early Phase 1 | Recruiting | YANRU WANG | 21 | 2025-05-06 | 2025-07-10 |
| Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma ssCART-19 - B Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Shanghai Tongji Hospital, Tongji University School of Medicine | 50 | 2025-04-22 | 2025-06-05 |
| Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma. Incidence of acute kidney injury, Describe risk factors in AKI occurrence., Focus on patient with chronic kidney disease at baseline - Acute Kidney Injury (AKI), Infusion of CD19 CAR T Cell | Active not recruiting | Hospices Civils de Lyon | 300 | 2025-04-01 | 2025-08-03 | |
| A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) Sonrotoclax, Zanubrutinib, Placebo - Mantle Cell Lymphoma, B Cell Lymphoma | Phase 3 | Recruiting | BeOne Medicines | 300 | 2025-03-05 | 2026-09-28 |
| Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma ssCART-19 - B Cell Lymphoma | Phase 1 | Recruiting | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 30 | 2025-01-23 | 2026-05-06 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors Single dose injection of certain dose of UWD-19, MMF Immunosuppression - B Cell Lymphoma, B Cell Leukemia | Early Phase 1 | Suspended | Wondercel Biotech (ShenZhen) | 30 | 2024-10-24 | 2026-05-07 |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies CTX131 - T Cell Lymphoma, B Cell Lymphoma | Phase 1 / Phase 2 | Completed | CRISPR Therapeutics | 12 | 2024-08-13 | 2026-04-03 |
| Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma Early Palliative Care - Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | Not applicable | Recruiting | University Health Network, Toronto | 144 | 2024-07-18 | 2025-12-03 |
| A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma Glofitamab, Obinutuzumab, Axi-cel - B Cell Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-05-07 | 2026-09-24 |
| Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies CAR-T cell - B Cell Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Recruiting | Shenzhen University General Hospital | 10 | 2024-04-20 | 2026-05-13 |
| Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis Cytomegalovirus Infections, Acute Leukemia | Unknown | Assistance Publique - Hôpitaux de Paris | 250 | 2024-04-17 | 2024-07-17 |
Showing 20 of 77. Sign in to see all of them.
Lymphoma, B-Cell (77) · Leukemia, B-Cell (14) · Lymphoma (12) · Lymphoma, Non-Hodgkin (11) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (10) · Lymphoma, Follicular (8) · Lymphoma, Large B-Cell, Diffuse (7) · Burkitt Lymphoma (6) · Lymphoma, Mantle-Cell (6) · Leukemia (4) · Leukemia, Myeloid, Acute (4) · Multiple Myeloma (4) · Recurrence (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, B-Cell, Marginal Zone (3)
Hemic and Lymphatic Diseases (77) · Immune System Diseases (77) · Immunoproliferative Disorders (77) · Lymphatic Diseases (77) · Lymphoproliferative Disorders (77) · Neoplasms by Histologic Type (77) · Neoplasms (75) · Lymphoma, Non-Hodgkin (66) · Lymphoma (65) · Hematologic Diseases (31) · Leukemia (23) · Leukemia, Lymphoid (23) · Disease Attributes (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8)
Cyclophosphamide (7) · Rituximab (6) · fludarabine (6) · Immunotherapy, Adoptive (3) · CTL019 chimeric antigen receptor (2) · Doxorubicin (2) · Injections (2) · Prednisone (2) · Vincristine (2) · ibrutinib (2) · zanubrutinib (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Antibiotic Prophylaxis (1) · Antigens, CD19 (1) · Bendamustine Hydrochloride (1)
National Cancer Institute (NCI) (4) · Wuhan Sian Medical Technology Co., Ltd (4) · Chinese PLA General Hospital (3) · Assistance Publique - Hôpitaux de Paris (2) · Caribou Biosciences, Inc. (2) · Chongqing Precision Biotech Co., Ltd (2) · Henan Cancer Hospital (2) · Nanfang Hospital, Southern Medical University (2) · Shanghai Tongji Hospital, Tongji University School of Medicine (2) · Tel-Aviv Sourasky Medical Center (2) · The First Affiliated Hospital of Soochow University (2) · Yan'an Affiliated Hospital of Kunming Medical University (2) · iCell Gene Therapeutics (2) · Alliance Foundation Trials, LLC. (1) · Ascentage Pharma Group Inc. (1)
China (39) · United States (24) · France (6) · Australia (3) · Israel (3) · Austria (2) · South Korea (2) · United Kingdom (2) · Argentina (1) · Belarus (1) · Brazil (1) · Canada (1) · Germany (1) · Italy (1) · Japan (1)
Fang Liu, MD, PhD (2) · Heng Mei, M.D., Ph.D (2) · Hongyu Zhang, MD, PhD (2) · Ron Ram, Prof. (2) · YU HU, M.D., Ph.D (2) · Aibin Liang, MD,Ph.D. (1) · Alissa Keegan, MD, PhD (1) · Anas Younes, M.D. (1) · Andreas Holbro, Prof. Dr. (1) · Angelica Loskog, PhD (1) · Armin Ghobadi, M.D. (1) · Breffni Hannon, MB BCh BAO, MMedSci, MCFP (1) · Brian Hill, MD, PhD (1) · Cheng Qian, PhD (1) · DH Yang, M.D, Ph.D (1)
PMID 40195173, PMID 35799791, PMID 22965964, PMID 24382970, PMID 24782509, PMID 24963497, PMID 25317870, PMID 25319501, PMID 27632680, PMID 28251914, PMID 29061568, PMID 29437592, PMID 30097433, PMID 30178481, PMID 31196847, PMID 32209572, PMID 32840736, PMID 32883871, PMID 33764809, PMID 34515338, PMID 34687939, PMID 34935483, PMID 35148417, PMID 37486616, PMID 38376944, PMID 39351902, PMID 39396632, PMID 40426201
2025 (1)